Literature DB >> 9535397

Reduced E-cadherin immunohistochemical expression in node-negative breast carcinomas correlates with 10-year survival.

C Charpin1, S Garcia, P Bonnier, F Martini, L Andrac, R Choux, M N Lavaut, C Allasia.   

Abstract

E-cadherin immunodetection was performed on frozen sections, using an immunoperoxidase procedure and with computer-assisted analysis of digitized colored microscopic images in a series of 179 breast carcinomas. Quantitative immunocytochemical assays were correlated with follow-up (129 months). The results showed that reduced E-cadherin immunocytochemical expression in tumors (cut point, 4%) significantly correlated with shorter overall survival in node-negative patients (Kaplan Meier log rank test). But E-cadherin immunostained expression (cut point, 4%) did not correlate with metastasis-free or recurrence-free survival. In multivariate analysis (Cox proportional hazards regression model), E-cadherin prognostic significance for overall survival in node-negative patients was independent of the tumor size, grade, and histologic type. The results suggest that reduced E-cadherin expression detected in optimum technical conditions (frozen samples and quantitative immunohistochemistry) is an independent indicator of poor survival in node-negative patients and may be clinically relevant for the treatment of patients with breast carcinomas.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9535397     DOI: 10.1093/ajcp/109.4.431

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  12 in total

Review 1.  Cadherin junctions in mammary tumors.

Authors:  M J Wheelock; A P Soler; K A Knudsen
Journal:  J Mammary Gland Biol Neoplasia       Date:  2001-07       Impact factor: 2.673

Review 2.  Regulation of breast cancer metastasis signaling by miRNAs.

Authors:  Belinda J Petri; Carolyn M Klinge
Journal:  Cancer Metastasis Rev       Date:  2020-09       Impact factor: 9.264

3.  Influence of chemically modified tetracyclines on proliferation, invasion and migration properties of MDA-MB-468 human breast cancer cells.

Authors:  Q Meng; J Xu; I D Goldberg; E M Rosen; R A Greenwald; S Fan
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

4.  Epithelial-mesenchymal transition markers in lymph node metastases and primary breast tumors - relation to dissemination and proliferation.

Authors:  Aleksandra Markiewicz; Marzena Wełnicka-Jaśkiewicz; Barbara Seroczyńska; Jarosław Skokowski; Hanna Majewska; Jolanta Szade; Anna J Żaczek
Journal:  Am J Transl Res       Date:  2014-11-22       Impact factor: 4.060

5.  Expression of P-cadherin, but not E-cadherin or N-cadherin, relates to pathological and functional differentiation of breast carcinomas.

Authors:  A Kovács; J Dhillon; R A Walker
Journal:  Mol Pathol       Date:  2003-12

6.  E-Cadherin as a diagnostic biomarker in breast cancer.

Authors:  Rajeev Singhai; Vinayak W Patil; Sanjog R Jaiswal; Shital D Patil; Mukund B Tayade; Amit V Patil
Journal:  N Am J Med Sci       Date:  2011-05

7.  Significance of E-cadherin expression in triple-negative breast cancer.

Authors:  S Kashiwagi; M Yashiro; T Takashima; S Nomura; S Noda; H Kawajiri; T Ishikawa; K Wakasa; K Hirakawa
Journal:  Br J Cancer       Date:  2010-06-15       Impact factor: 7.640

8.  Advantages of adjuvant chemotherapy for patients with triple-negative breast cancer at Stage II: usefulness of prognostic markers E-cadherin and Ki67.

Authors:  Shinichiro Kashiwagi; Masakazu Yashiro; Tsutomu Takashima; Naoki Aomatsu; Katsumi Ikeda; Yoshinari Ogawa; Tetsuro Ishikawa; Kosei Hirakawa
Journal:  Breast Cancer Res       Date:  2011-11-30       Impact factor: 6.466

9.  An expression signature of syndecan-1 (CD138), E-cadherin and c-met is associated with factors of angiogenesis and lymphangiogenesis in ductal breast carcinoma in situ.

Authors:  Martin Götte; Christian Kersting; Isabel Radke; Ludwig Kiesel; Pia Wülfing
Journal:  Breast Cancer Res       Date:  2007       Impact factor: 6.466

10.  Quantitative immunohistochemical expression of c Kit in breast carcinomas is predictive of patients' outcome.

Authors:  C Charpin; S Giusiano; S Charfi; V Secq; S Carpentier; L Andrac; M-N Lavaut; C Allasia; P Bonnier; S Garcia
Journal:  Br J Cancer       Date:  2009-06-09       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.